Obesity and Menopausal Status in Breast Cancer
Clifford A. Hudis, MD, discusses obesity and menopausal status as determinants of procarcinogenic breast inflammation.
Clinical Pearls
Clifford A. Hudis, MD, Chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses obesity and menopausal status as determinants of procarcinogenic breast inflammation.
- The peak incidence of hormone-sensitive breast cancer occurs in the decade after menopause.
- There is an association between hormone-sensitive breast cancer and obesity.
- Some of the inflammatory mediators that are generated in the fat tissue of obese patients are stimulants for the production of aromatase, and thereby, estrogen.
- Predictors of these inflammatory mediators in the breast include both obesity and the postmenopausal state. This suggests that after menopause, there is a low-grade, chronic systemic inflammation in some people that may contribute to postmenopausal breast cancer.
<<<
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
